SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies receives renewal of recognition for in-house R&D excellence by DSIR

16 May 2023 Evaluate

Venus Remedies has received renewal of recognition for its in-house R&D excellence by the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, Government of India. This renewal underscores Venus Remedies' commitment to innovation, excellence in research, and its significant contributions to healthcare. With 15 patented products brought to market and several others in the pipeline, company's R&D portfolio demonstrates a progressive approach to drug development.  The company has consistently invested in research and development. The company invested 3.53% of its total sales in R&D, from which it has generated 5.25% of its total revenue, which stood at Rs 575.18 crore in FY 2021-22. The R&D spend for the same period amounted to Rs 20.31 crore.

This renewal of recognition from DSIR reinforces company’s position as a research-driven pharmaceutical company dedicated to bringing innovative and effective solutions to address global healthcare needs. 

The company has emerged as a pioneer in developing innovative medical solutions to combat antibiotic resistance, a global health concern. As part of its commitment to addressing antimicrobial resistance, VRL has created a range of patented superbug-fighting solutions, including Elores. In recognition of its efforts to combat antimicrobial resistance, Venus Remedies has become a member of the AMR Industry Alliance (AMRIA), joining over 100 globally renowned organizations in a coordinated response to this critical issue.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. 

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×